ライフサイエンスコーパス: relative risk

1 p to 4.2% (3.3-5.2) in the atraumatic group (relative risk 0.40, 95% CI 0.34-0.47, p<0.0001; I(2)=45.

2 risk difference was -0.65% (-1.01 to -0.29; relative risk 0.61, 0.39 to 0.83; number needed to treat

3 of birth was -0.88% (95% CI -1.15 to -0.61; relative risk 0.69, 95% CI 0.60 to 0.78; number needed t

4 8, 95% CI 0.785-1.005, 0=0.061, and adjusted relative risk 0.873, 0.776-0.982, p=0.023).

5 Age (relative risk 0.88, 95% CI 0.86-0.90; p<0.0001), medical

6 0.16 [0.06-0.39]; p = 0.0001), and 3 hours (relative risk = 0.09 [0.03-0.27]; p < 0.0001).

7 sk = 0.20 [0.09-0.45]; p = 0.0001), 4 hours (relative risk = 0.16 [0.06-0.39]; p = 0.0001), and 3 hou

8 The relative risk = 0.2 greatly reduces the bias linked to t

9 who received traditional therapy (P < 0.05, relative risk = 0.2).

10 ), antibiotic administration within 6 hours (relative risk = 0.20 [0.09-0.45]; p = 0.0001), 4 hours (

11 atively associated with diagnosed STI rates (relative risk = 0.3, 95% confidence interval: 0.2, 0.7).

12 d with a 23% reduction in the risk of death: relative risk = 0.77 (95% CI, 0.71-0.83); p value of les

13 pse between 8 weeks and 12 weeks of LDV/SOF (relative risk = 0.99, 95% confidence interval 0.98-1.00)

14 (95% CI: 14, 19) per 10 000 administrations (relative risk, 0.12 [95% CI: 0.05, 0.31]; P < .001).

15 5% CI: 7.5, 9.2) per 10 000 administrations (relative risk, 0.19 [95% CI: 0.099, 0.36]; P < .00001) a

16 of 99 patients in the primary surgery group (relative risk, 0.25; 95% CI, 0.13 to 0.47; P < .001).

17 days with EBV detected from 61.3% to 17.8% (relative risk, 0.28; 95% confidence interval [CI], .21-.

18 nd lower admission Glasgow Coma Scale score (relative risk, 0.34; 95% CI, 0.20-0.58; for one unit inc

19 The generational association (relative risk, 0.40; 95% CI, 0.28 to 0.57) remained sign

20 difference, -8.0% [95% CI, -15.7% to -0.4]; relative risk, 0.48 [95% CI, 0.24-0.95]).

21 5%) in restricted visitation model (adjusted relative risk, 0.50; 95% CI, 0.26-0.95).

22 th recipients of AKI donor kidneys (adjusted relative risk, 0.51 [95% confidence interval (95% CI), 0

23 (22 patients [5.7%] vs. 20 patients [11.3%]; relative risk, 0.51; 95% CI, 0.29 to 0.91; P=0.04), but

24 between refills in all age groups (adjusted relative risk, 0.54; 95% CI, 0.32 to 0.92).

25 and lower for internal jugular than femoral (relative risk, 0.55 [95% CI, 0.34-0.89]; I = 61%).

26 group in 60 (22.2%) vs 103 (38.1%) patients (relative risk, 0.58; 95% CI, 0.44-0.77; NNT, 6; 95% CI,

27 allergy (egg 7.0% vs control 10.3%; adjusted relative risk, 0.75; 95% CI, 0.48-1.17; P = .20).

28 cks apoC-III was associated with lower risk (relative risk, 0.76; 95% confidence interval, 0.70-0.83)

29 ecipients of non-AKI donor kidneys (adjusted relative risk, 0.79 [95% CI, 0.65 to 0.97]).

30 tion compared with referent states (adjusted relative risk, 0.79; 95% confidence interval, 0.73-0.85;

31 gative than the relative risk for total HDL (relative risk, 0.80; 95% confidence interval, 0.74-0.87)

32 unchanged after the policy change (adjusted relative risk, 0.82; 95% confidence interval, 0.76-0.89;

33 tients (55.4%) in the multivessel PCI group (relative risk, 0.83; 95% confidence interval [CI], 0.71

34 Younger age (relative risk, 0.87; 95% CI, 0.79-0.94; for 1 yr increas

35 onths in 197 (73.0%) vs 222 (82.2%) infants (relative risk, 0.89; 95% CI, 0.81-0.98; number needed to

36 he 716 patients (1.8%) in the control group (relative risk, 0.8; 95% CI, 0.3 to 1.7; absolute differe

37 and 39% [48 of 124 patients], respectively; relative risk, 0.92; 95% confidence interval [CI], 0.67

38 n 420 patients (18.1%) in the placebo group (relative risk, 0.92; 95% confidence interval, 0.81 to 1.

39 ospital mortality in the randomized studies (relative risk, 0.93; 95% CI, 0.77-1.13; I = 0.0%) or obs

40 HF hospitalizations and all-cause mortality (relative risk, 0.93; 95% CI, 0.87-1.00; P=0.04; I(2)=39.

41 between the 2 groups in HF hospitalizations (relative risk, 0.94; 95% CI, 0.70-1.26; P=0.68; I(2)=52.

42 ARBs decreased all-cause mortality modestly (relative risk, 0.94; 95% confidence interval (CI), 0.89-

43 I(2)=52.8%) and all-cause hospitalizations (relative risk, 0.97; 95% CI, 0.85-1.11; P=0.67; I(2)=31.

44 es between groups in either clinical (CGI-I: relative risk 1.01, 95% CI 0.86-1.19; p=0.95) or economi

45 hieve full immunisation at 12 months of age (relative risk 1.09, 95% CI 1.02-1.16, p=0.014) than chil

46 thers were not exposed to the vaccine (crude relative risk 1.32, 95% CI 0.46-3.84; p=0.60).

47 respectively, achieved the primary endpoint (relative risk 1.76, 95% CI 1.12-2.77, p=0.0045).

48 9 [1.00-1.18]; p = 0.04), presence of shock (relative risk = 1.007 [1.002-1.013]; p = 0.006), time-to

49 ompared with <1 year, multivariable-adjusted relative risk = 1.01, 95% confidence interval: 0.97, 1.0

50 Physiology and Chronic Health Evaluation II (relative risk = 1.05 [1.02-1.09]; p = 0.003), Sequential

51 interval: 1.07, 2.24) but not rectal cancer (relative risk = 1.07, 95% confidence interval: 0.68, 1.6

52 ; 95% CI, 1.04-1.16) and Hispanic ethnicity (relative risk = 1.08; 95% CI, 1.02-1.14) as independent

53 0.003), Sequential Organ Failure Assessment (relative risk = 1.09 [1.00-1.18]; p = 0.04), presence of

54 ompared with <1 year, multivariable-adjusted relative risk = 1.09, 95% confidence interval: 1.04, 1.1

55 ompared with <1 year, multivariable-adjusted relative risk = 1.10, 95% confidence interval: 1.06, 1.1

56 multivariate analysis identified black race (relative risk = 1.10; 95% CI, 1.04-1.16) and Hispanic et

57 as independently associated with longer LOS [relative risk = 1.15, 95% confidence interval (CI): 1.03

58 .013]; p = 0.006), time-to-first antibiotic (relative risk = 1.22 [1.09-1.36]; p = 0.0006), antibioti

59 ghest tertile of use vs. never use, adjusted relative risk = 1.32, 95% confidence interval (CI): 1.08

60 risk of colon cancer (multivariable-adjusted relative risk = 1.54, 95% confidence interval: 1.07, 2.2

61 fter PCI in patients with versus without DM (relative risk, 1.04; range, 0.80-1.36).

62 and 46% [74 of 161 patients], respectively; relative risk, 1.07; 95% CI, 0.85 to 1.34; P=0.56).

63 al doctor and received antiasthma treatment (relative risk, 1.07; 95% CI, 0.89-1.28).

64 extremely obese (body mass index, >/= 50.0; relative risk, 1.10; 95% CI, 1.05-1.15).

65 , normal weight (body mass index, 18.5-24.9; relative risk, 1.10; 95% CI, 1.09-1.12), and the extreme

66 f the infants in the control group (adjusted relative risk, 1.11; 95% CI, 1.00 to 1.23; P=0.045).

67 %) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61-2.09; I = 61.0%) were

68 Shock reversal (relative risk, 1.13; 95% CI, 0.68-1.90; I = 51.6%) and a

69 ump group versus 27.1% in the on-pump group (relative risk, 1.14; 95% CI, 1.00 to 1.30; P=0.046).

70 being associated with longer length of stay (relative risk, 1.17; 95% CI, 1.09-1.26; P < .001).

71 a less increased relative risk of mortality (relative risk, 1.19 (1.08-1.31); P<0.001), compared with

72 ted with increased antibiotic-days (adjusted relative risk, 1.1; 95% confidence interval [CI], 1.15-1

73 who had never used hormonal contraceptives (relative risk, 1.21; 95% CI, 1.11 to 1.33).

74 d transfusion (absolute risk, 1.8% vs. 1.5%; relative risk, 1.23; 95% CI, 1.13 to 1.34; P<0.001).

75 ump group versus 11.9% in the on-pump group (relative risk, 1.28; 95% confidence interval [CI], 1.03

76 site bleeding (absolute risk, 0.4% vs. 0.3%; relative risk, 1.34; 95% CI, 1.10 to 1.62; P=0.001) and

77 among underweight (body mass index, < 18.5; relative risk, 1.35; 95% CI, 1.32-1.39), normal weight (

78 us 57 (29.5%) in the control group (adjusted relative risk, 1.37 [95% CI, 1.02 to 1.75]).

79 atients) for all other botulinum antitoxins (relative risk, 1.41 [95% confidence interval, .47-4.27];

80 of aGVHD (relative risk, 2.75, P = .006 and relative risk, 1.42, P = .02, respectively).

81 .001), compared with WRF induced by placebo (relative risk, 1.48 (1.35-1.62); P<0.001; P for interact

82 osure devices (absolute risk, 1.2% vs. 0.8%; relative risk, 1.59; 95% confidence interval [CI], 1.42

83 he 720 patients (0.4%) in the control group (relative risk, 1.6; 95% confidence interval [CI], 0.4 to

84 ith favorable neurological outcome (adjusted relative risk, 1.6; 95% confidence interval, 1.1-2.5; P=

85 en with HPV testing vs 6.6% without testing (relative risk, 1.76; 95% CI, 1.56-2.00; P < .001).

86 ciated with early treatment discontinuation (relative risk, 1.79; 95% CI, 1.53 to 2.10 for overall wo

87 ) and was associated with survival (adjusted relative risk, 1.7; 95% confidence interval, 1.2-2.6; P=

88 difference, +40.7% [95% CI, +30.1%-+50.3%]; relative risk, 1.88 [95% CI, 1.57-2.27]).

89 red with 9 of 87 (10.3%) in the BLISS group (relative risk, 1.8; 95% CI, 0.6-5.7).

90 risk, 2.04; 95% CI, 1.37-3.04) and response (relative risk, 1.96; 95% CI, 1.60-2.40).

91 the daily TMP-SMX alone arm (6.1% vs. 3.1%; relative risk, 1.96; 95% confidence interval, .50-7.61;

92 r moderately preterm birth (32 to 36 weeks) (relative risk: 1.36; 95% CI: 0.87 to 2.13).

93 dently increased the risk of bladder cancer, relative risk, 11.7 (P = 0.0013) and 5.6 (P = 0.0053), r

94 specific IgE levels significantly increased (relative risk, 19.42; 95% CI, 8.7-43.7; P < .001).

95 ry anxiety symptoms and increased remission (relative risk, 2.04; 95% CI, 1.37-3.04) and response (re

96 2.6% in the placebo group (primary outcome; relative risk, 2.20; 95% CI, 0.68-7.14; P = .24), and 2.

97 zation risk was higher for internal jugular (relative risk, 2.25 [95% CI, 1.84-2.75]; I = 0%) and fem

98 clavian, higher for femoral than subclavian (relative risk, 2.44 [95% CI, 1.25-4.75]; I = 61%), and l

99 t risk factors for the development of aGVHD (relative risk, 2.75, P = .006 and relative risk, 1.42, P

100 ures with bivalirudin (7 [2.1%] vs 7 [0.7%]; relative risk, 2.87; 95% CI, 1.01-8.17; P = .04) but not

101 25 [95% CI, 1.84-2.75]; I = 0%) and femoral (relative risk, 2.92 [95% CI, 2.11-4.04]; I = 24%), compa

102 up and 13/148 (8.8%) in the resection group (relative risk 3.01, 95% confidence interval 1.15-7.90).

103 , 2.2 to 11.0), and with preterm SGA births (relative risk 3.0; 95% CI, 2.1 to 4.4).

104 ation in risk of gallbladder cancer (sibling relative risk 3.15 [95% CI 1.80-5.49]).

105 delivery was linked to CKD stage (2-5 vs 1: relative risk 3.42 and 3.78) and hypertension (RR 3.68 a

106 h three (10%) patients in the placebo group (relative risk 3.93, 95% CI 1.31-11.81; p=0.0026).

107 5% CI: 4.5, 6.0) per 10 000 administrations (relative risk, 3.1 [95% CI: 2.4, 3.8]; P < .0001).

108 gg allergy versus 0.6% in the placebo group (relative risk, 3.30; 95% CI, 0.35-31.32; P = .35).

109 ] of 203 patients v 34 [6%] of 602 patients; relative risk, 3.3; 95% CI, 2.1 to 5.1; P < .001).

110 ve compared with negative resection margins (relative risk 4.8, 95% CI 3.2-7.2).

111 The adjusted relative risk (95% CI) for bevacizumab relative to ranib

112 In multivariable models (relative risk [95% confidence interval]), male sex (2.7

113 e 613 infants assigned to the control group (relative risk adjusted for randomization strata, 1.13; 9

114 We also compared predicted bias in estimated relative risks adjusted using 24HRs as reference instrum

115 who never used hormonal contraceptives, the relative risk among current and recent users was 1.97 (9

116 MSM were compared through calculation of the relative risk and 95% confidence intervals.

117 A two-stage approach was used to estimate relative risks and 95% confidence intervals (CIs) from C

118 We used Poisson regression to estimate relative risks and 95% confidence intervals for the rela

119 ial regression analysis was used to estimate relative risks and 95% confidence intervals.

120 plus vancomycin is increasing; however, the relative risks and benefits associated with this strateg

121 We aimed to compare the relative risks and benefits of these interventions.

122 Sex-specific incidence rate ratios (IRRs; relative risks) and cumulative incidence percentage valu

123 pital-level mean score for respect [adjusted relative risk (aRR) 0.78, 95% CI 0.65-0.93, P = 0.0059],

124 Adjusted relative risk (aRR) of mortality at 5 years was 79% lowe

125 for the usual activities item; the adjusted relative risk (ARR) of reporting problems decreased from

126 er risk of immediate complications (adjusted relative risk [aRR] 0.44 [95% CI 0.36-0.55]) and subsequ

127 g Poisson regression, we calculated adjusted relative risks (ARRs) for adverse outcomes of pregnancy

128 The relative risks associated with mutagen exposure compared

129 regression models to determine the adjusted relative risk, attributable risk, and number needed to h

130 f IBS after infectious enteritis, as well as relative risk (compared with individuals without infecti

131 In the meta-analysis, the relative risks comparing the top versus the bottom tropo

132 95% confidence interval, 0.7 to 6.0; P=0.01; relative risk difference, 13.3%).

133 tributable to O3 exposures using the updated relative risk estimate and exposure parameters, compared

134 term annual O3 exposure based on the updated relative risk estimates and minimum risk thresholds set

135 Updated relative risk estimates are now available for the same c

136 Relative risk estimates as odds ratios (ORs) with 95% co

137 Missing data may affect absolute and relative risk estimates differently and should be consid

138 Relative risk estimates for long-term ozone (O3) exposur

139 than in the early cord clamping group and a relative risk for anemia of 0.91 (95% CI, 0.84-0.98), re

140 We determined the relative risk for CRC for individuals based on age and n

141 brain function may be a useful biomarker of relative risk for depression in the context of negative

142 d brain function as a potential biomarker of relative risk for depression.SIGNIFICANCE STATEMENT Slee

143 The relative risk for HDL lacking apoC-III was even more neg

144 -0.56 to 0.13; P = .22), histologic scores (relative risk for histologic findings in patients who co

145 evidence of much higher radiation-associated relative risk for male than for female breast cancer, al

146 Patients without a breast pCR had a relative risk for positive nodal metastases of 7.4 (95%

147 The adjusted relative risk for pregnancy loss among those exposed to

148 ing apoC-III was even more negative than the relative risk for total HDL (relative risk, 0.80; 95% co

149 The relative risk for unnatural death (IRR, 25.0; 95% CI, 22

150 Adjusted relative risks for 12-month eGFR less than 30 mL/min per

151 Relative risks for a history of HF before RA onset were

152 (>/=37 weeks' gestation), adjusted incidence relative risks for HF were 17.0 (95% confidence interval

153 The reported relative risks for thrombosis, any bleeding, and major b

154 h BMI and incidence of cancer, combined with relative risks from published estimates, to quantify con

155 Adjusted relative risks, incidence rate ratios, and 99% confidenc

156 (15.1%) control individuals, representing a relative risk of 0.44 in the mHELP group (95% CI, 0.23-0

157 ident-days or 3.9% over 6 months; unadjusted relative risk of 0.888, 95% CI 0.785-1.005, 0=0.061, and

158 rence of 4.7% (95% CI, -1.8% to 11.2%) and a relative risk of 1.28 (95% CI; 0.92 to 1.78; P = .14).

159 erence of 8.7% (95% CI, 1.2% to 16.2%) and a relative risk of 1.31 (95% CI, 1.02 to 1.68; P = .03).

160 rence of 10.3% (95% CI, 0.6% to 20.1%) and a relative risk of 1.37 (95% CI, 1.01 to 1.87; P = .046).

161 ssing these sources, we identified a summary relative risk of 1.59 (95% confidence interval: 0.70, 3.

162 a first-degree relative affected by AF had a relative risk of 1.92 (95% CI, 1.84-1.99) for AF.

163 and one in the no-exposure group, yielding a relative risk of 2.00 (95% CI 0.18-22.04; p=0.57), altho

164 ation, compared to 0.14 among non-MSM, for a relative risk of 4.0 (95% confidence interval [CI], 3.1-

165 To estimate relative risk of acute pancreatitis, by degree of severi

166 y variable for disparities in AAs; the crude relative risk of acute rejection in AAs was reduced by 4

167 Our simulations indicated that the relative risk of adult obesity increased with age and BM

168 The prevalence and relative risk of AF in relatives of patients with AF, as

169 Patients and Methods Excess relative risk of all-cause death in black versus white w

170 Odds ratios (ORs) were used to measure the relative risk of BDI and BDII in relatives of individual

171 o had never used hormonal contraception, the relative risk of breast cancer among all current and rec

172 We observed a 1.42-fold excess relative risk of cancer in subjects with PIDD compared w

173 e IER estimator may underestimate the excess relative risk of cause-specific mortality due to long-te

174 The pooled relative risk of CDI in probiotic users was 0.42 (95% co

175 e-POCT achieved a 49% reduction in the relative risk of clinical failure compared to routine ca

176 BACKGROUND & AIMS: Relative risk of colorectal cancer (CRC) decreases with

177 The relative risk of conversion to a diagnosis of PD in hypo

178 Relative risk of death among patients treated with antit

179 At week 52, the relative risk of death for all four mortality outcomes w

180 t delay the onset of ESRD but may reduce the relative risk of death in CKD.

181 The relative risk of death in the culprit-lesion-only PCI gr

182 s 0.88 (95% CI, 0.78 to 1.00) and unadjusted relative risk of death was 0.87 (95% CI, 0.76 to 0.99) f

183 ic episodes have an approximately equivalent relative risk of developing depression episodes and anxi

184 PEP effectiveness [(1 - relative risk of developing measles) x 100] was calculat

185 holiday period was marked by a shift in the relative risk of disease from children toward adults.

186 The relative risk of districts reaching the epidemic thresho

187 Relative risk of dying in intensive care for recent immi

188 We calculated the relative risk of dying of brain cancers for each municip

189 rom the MDRD and the AASK trials, unadjusted relative risk of ESRD was 0.88 (95% CI, 0.78 to 1.00) an

190 Regression models were used to determine relative risk of GDM (n = 140 cases) in relation to heal

191 This study sought to investigate the relative risk of HF overall and by subtype (ischemic and

192 The relative risk of HFpEF increases with increasing cardiac

193 The overall relative risk of HH associated with a heatwave episode w

194 The relative risk of HH associated with the first heatwave i

195 The relative risk of hospice claims within 180 d of a NaF PE

196 s also associated with a significantly lower relative risk of incident CKD stage 3b or higher (hazard

197 ectomy associated with a significantly lower relative risk of incident CKD stage 4 or higher (hazard

198 therapy was associated with a less increased relative risk of mortality (relative risk, 1.19 (1.08-1.

199 herapy is associated with a reduction in the relative risk of mortality compared with placebo over 12

200 ns for each cause of death, we estimated the relative risk of mortality from ischaemic heart disease,

201 st error estimates were used to estimate the relative risk of outcomes.

202 Relative risk of PF associated with pasireotide was esti

203 efficacious maintenance therapy reducing the relative risk of progression in first-line patients with

204 Early CCY reduced relative risk of recurrent biliary events within 60 days

205 The relative risk of relapse of quiescent inflammatory bowel

206 0.84 (95% CI, 0.72 to 0.98; P=0.03), and the relative risk of renal-replacement therapy was 0.71 (95%

207 The relative risk of resolution increased in those cases wit

208 The pooled relative risk of stroke mortality was 1.57 (95% CI, 1.04

209 The purpose of this study was to assess the relative risk of suicide attempt and suicide in users of

210 nd performed a meta-analysis to estimate the relative risk of TB incidence and its 95% confidence int

211 ing the summer months and an increase in the relative risk of these infections in the coming decades.

212 ls and humans, it was critical to assess the relative risk of this novel virus to public health.

213 We assessed the relative risk of type 2 diabetes prospectively for each

214 nts between these two anti-VEGF drugs; i.e., relative risks of >/=1.5 are unlikely.

215 ice the effect of Model C on MC uptake, with relative risks of 2.4 (95%CI, 1.5-3.8) and 2.2 (95%CI, 1

216 atio (AER) values were calculated to compare relative risks of activating the aryl hydrocarbon recept

217 The pooled relative risks of any stroke were 1.21 (95% CI, 1.06-1.3

218 The pooled relative risks of any stroke were 1.42 (95% CI, 1.34-1.5

219 ed random-effects meta-analyses to summarise relative risks of being widowed, divorced or lifelong si

220 Relative risks of GBCA types were estimated by using the

221 Relative risks of incident HF in RA were calculated as h

222 In men, the pooled relative risks of ischemic stroke were 1.19 (95% CI, 1.0

223 In women, the pooled relative risks of ischemic stroke were 1.80 (95% CI, 1.4

224 We calculated relative risks of nausea improvement using stratified Co

225 The relative risks of outcomes were estimated by Poisson reg

226 There are increased odds ratios or relative risks of several gastrointestinal complications

227 Compared with women given FA, the relative risks of SPB for those using MMN and IFA were 0

228 To assess patterns of use and relative risks of systemic agents for moderate to severe

229 to generate pooled incidence rate ratios and relative risks, or risk differences.

230 edict future development of type 2 diabetes (relative risk per 1 standard deviation increase in methy

231 g, and outcome, and presented them as excess relative risk per 10 mug/m(3) increase in particulate am

232 associated with a higher risk of CHD (pooled relative risk per standard deviation, 1.09; 95% confiden

233 Generalized estimating equations estimated relative risks per interquartile-range increment for pol

234 ed, with patients who were aged 16-30 years (relative risk ratio [RRR] 1.21, 95% CI 1.19-1.23) or old

235 Adjusted relative risk ratios (aRRR) for associations of parental

236 We also quantified differences with relative risk ratios and relative and slope indices of i

237 ents with and without pCR and compared using relative risk ratios with 95% CIs.

238 uvastatin]), statin therapy led to a greater relative risk reduction among a subgroup at high genetic

239 tality (0.87, 0.79-0.96; p=0.007), and a 12% relative risk reduction in all-cause mortality (0.88, 0.

240 r agonist treatment showed a significant 10% relative risk reduction in the three-point major adverse

241 c risk, statin therapy was associated with a relative risk reduction of 44% (95% confidence interval

242 Based on previously reported data (relative risk reduction of 50%), the incremental gain in

243 22-60; P<0.001), whereas in all others, the relative risk reduction was 24% (95% CI, 8-37; P=0.004)

244 Relative risk reduction with statin therapy has been con

245 cidence of PME in patients without diabetes [relative risk (RR) 0.68, 95% confidence interval (CI) 0.

246 ions decreased by 32% on high snowfall days (relative risk (RR) = 0.68, 95% confidence interval (CI):

247 . red or blonde hair, multivariable-adjusted relative risk (RR) = 0.99, 95% confidence interval (CI):

248 r risk of poor self-reported general health (relative risk (RR) = 1.28; 95% confidence interval (CI):

249 h an elevated risk of newborn resuscitation (relative risk (RR) = 1.5, 99% confidence interval (CI):

250 eralized estimating equations calculated the relative risk (RR) and 95% confidence interval for early

251 AND Data were summarized as Mantel-Haenszel relative risk (RR) and 95% confidence intervals (CIs) fo

252 coexisting VHD to assess pooled estimates of relative risk (RR) and 95% confidence intervals (CIs) fo

253 dish Family-Cancer Database, we assessed the relative risk (RR) for any cancer in families with incre

254 ut AKI and reported a multivariable-adjusted relative risk (RR) for the association between AKI and c

255 ed incidence of CRC (Ptrend < .0001), with a relative risk (RR) of 1.31 (95% CI, 1.15-1.48, comparing

256 Relative risk (RR) of psoriasis was estimated by Cox reg

257 In current users, the relative risk (RR) per year of tamoxifen use was 0.76 (9

258 PCME relative risk (RR) was most significant in contralateral

259 ives include determining the incidence rate, relative risk (RR), and survival probability with respec

260 ns at a threshold of 16 degrees C revealed a relative risk (RR)=1.14 (95% CI: 1.02, 1.27; p=0.024) fo

261 ated with lower risk of all-cause mortality (relative risk [RR] 0.65, 95% CI 0.44-0.97, p=0.03) and r

262 (n=76; 33.9 cases per 10 000 exposure days; relative risk [RR] 0.70, 95% CI 0.50-0.98; p=0.036).

263 r rates per year in adults aged 19-64 years (relative risk [RR] 0.85, 95% CrI 0.75-0.95) and 65 years

264 ary infant composite outcome of death or CP (relative risk [RR] 0.94, 95% confidence interval (CI) 0.

265 s 43% (477/1,101) at the SOC sites (adjusted relative risk [RR] 1.52, 95% CI 1.19-1.96, p = 0.002).

266 160 patients in the control group, had died (relative risk [RR] of mortality 0.67, 95% CI 0.42-1.08;

267 nce interval included African American race (relative risk [RR] to white, 1.41; 95% confidence interv

268 risk of waitlist dropout due to progression (relative risk [RR], 0.32; 95% confidence interval [CI],

269 , discontinuation was lowest among children (relative risk [RR], 0.44 [95% confidence interval {CI},

270 ears after adjusting for common confounders (relative risk [RR], 0.46; 95% CI, 0.11-1.93).

271 duced risk of death from any cause (adjusted relative risk [RR], 0.67; 95% confidence interval [CI],

272 to less than 150/90 mm Hg reduces mortality (relative risk [RR], 0.90 [95% CI, 0.83 to 0.98]), cardia

273 statin discontinuation (moderate intensity: relative risk [RR], 0.93; 95% confidence interval [CI],

274 e same for both treatment groups (59 deaths; relative risk [RR], 1.02; 95% CI, 0.72-1.45; P = .92).

275 The likelihood of PCI at outlier (relative risk [RR], 1.13; 95% confidence interval [CI],

276 eased risk of death at 6 months (45% vs 39%; relative risk [RR], 1.16; 95% CI, 1.07-1.26) despite an

277 roup exceeded the switch group in remission (relative risk [RR], 1.30 [95% CI, 1.05-1.60]; P = .02),

278 f 5714] versus 15.5% [373 of 2405]; adjusted relative risk [RR], 1.49; 95% confidence interval [CI] 1

279 suicide, depression, alcoholism, or autism (relative risk [RR], 1.50; 95% CI, 1.08-2.17; P = .02).

280 hs vs 0.64 per 10000 person-months; adjusted relative risk [RR], 1.88; 95% CI, 1.34-2.64) and tricycl

281 d with a 70% reduction in recurrent syncope (relative risk [RR]: 0.30; 95% confidence interval [CI]:

282 ork meta-analysis revealed that varenicline (relative risk [RR]: 2.64; 95% confidence interval [CI],

283 and lowest quartiles of PM2.5, the adjusted relative risks (RRs) [95% confidence intervals (CIs)] of

284 We estimated relative risks (RRs) and 95% CIs of ID in children expos

285 Relative risks (RRs) and 95% CIs were calculated accordi

286 Poisson regression was used to compute relative risks (RRs) and 95% CIs, with adjustments for m

287 Poisson regression was used to estimate relative risks (RRs) and 95% confidence intervals (CIs)

288 mial regression models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs).

289 proportional hazards regression to estimate relative risks (RRs) for the association of PM2.5 with c

290 We obtained relative risks (RRs) of cervical cancer by screening his

291 Study specific relative risks (RRs) were aggregated using random-effect

292 hospital visits at lag 0-2 days (cumulative relative risk [RRs] 1.011 [95% CI 1.006-1.017] for a 10

293 isk factor for AMD in LSOCA was smoking; the relative risk vs never-smokers was 3.4 for former smoker

294 The largest relative risk was observed for the land-use regression m

295 The smallest relative risk was observed for the RS estimates that exc

296 ntakes, predicted bias in estimated nutrient relative risks was reduced on average, but bias in the e

297 For secondary outcomes, adjusted relative risks were 0.99 [ (0.69, 1.43); p=0.97] for dea

298 Summary relative risks were estimated using a random effects mod

299 Relative risks were greater in three prespecified high-r

300 multinomial regression to calculate adjusted relative risks with 95% confidence intervals.